KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short-term Investments: 2009-2024

Historic Short-term Investments for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $1.7 billion.

  • Alnylam Pharmaceuticals' Short-term Investments fell 26.17% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 26.17%. This contributed to the annual value of $1.7 billion for FY2024, which is 6.46% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Short-term Investments of $1.7 billion as of FY2024, which was up 6.46% from $1.6 billion recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Short-term Investments peaked at $1.7 billion during FY2024, and registered a low of $1.3 billion during FY2022.
  • Its 3-year average for Short-term Investments is $1.5 billion, with a median of $1.6 billion in 2023.
  • Its Short-term Investments has fluctuated over the past 5 years, first spiked by 36.73% in 2020, then decreased by 16.19% in 2022.
  • Alnylam Pharmaceuticals' Short-term Investments (Yearly) stood at $1.3 billion in 2020, then grew by 16.16% to $1.5 billion in 2021, then dropped by 16.19% to $1.3 billion in 2022, then grew by 24.47% to $1.6 billion in 2023, then increased by 6.46% to $1.7 billion in 2024.